{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.152","value":"-2.44"},{"groupId":"OG001","spread":"1.109","value":"-2.48"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"70"}],"units":"Participants"}],"description":"DAS modified included the 28 diarthroidal joint count (DAS28) that consisted of a composite score of the following variables: TJC28, SJC28, CRP (mg/L), and PtGADA on a 0 to 100 mm VAS (0mm=no arthritis activity to 100 mm= extremely active arthritis). DAS28 calculated as: DAS28-CRP = 0.56(square root of TJC28)+0.28(square root of SJC28)+0.36\\[ln(CRP +1)\\]+0.014(VAS)+0.96. A decrease in DAS28-CRP indicated an improvement in participant's condition.","dispersionType":"Standard Deviation","groups":[{"description":"Participants on background methotrexate therapy who were administered 1 mg, 2 mg, 4 mg baricitinib (LY3009104) capsule or identical placebo capsule, orally once daily for 12 weeks in Part A received 4 mg baricitinib (LY3009104) and 1 placebo tablet orally once daily for 52 weeks in Part B.","id":"OG000","title":"Combined 4 mg Baricitinib (LY3009104)"},{"description":"Participants on background methotrexate therapy who were administered 1 mg, 2 mg, 8 mg baricitinib (LY3009104) capsules orally once daily for 12 weeks in Part A received 2 x 4 mg baricitinib (LY3009104) tablets orally once daily for 52 weeks in Part B.","id":"OG001","title":"Combined 8 mg Baricitinib (LY3009104)"}],"paramType":"MEAN","populationDescription":"All randomized participants who received any study drug in Part B and had DAS28-CRP evaluated at analysis time points. The last non-missing post-baseline value in Part B was used.","reportingStatus":"POSTED","timeFrame":"Baseline, 64 weeks","title":"Mean Change From Baseline to Week 64 in DAS Based on the 28 Diarthrodial Joint Count and CRP Level (DAS28-CRP)","type":"SECONDARY","unitOfMeasure":"units on a scale"}